Navigation Links
YM BIOSCIENCES' NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
Date:1/5/2009 

    Singapore investigators to coordinate 700 patient trial of EGFR targeting
    antibody for treatment of head and neck cancer

MISSISSAUGA, ON, Jan. 5 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that the National Cancer Centre of Singapore (NCCS) has selected nimotuzumab, YM's EGFR-targeting drug, for evaluation in a multinational Phase III trial of more than 700 patients with cancers of the head and neck. The NCCS stated that it selected nimotuzumab because of its reported preferential safety profile compared with other EGFR-targeting cancer drugs. The trial is sponsored by the NCCS in collaboration with Innogene Kalbiotech Pte. Ltd, ("IGK") YM's licensee for nimotuzumab for the region.

"The efficacy of nimotuzumab as an epidermal growth factor receptor targeted therapy is likely to be comparable to drugs of the same class. However, what is likely to set nimotuzumab apart is its low toxicity and favourable safety profile," said Dr. Rikrik Ilyas, Director of IGK. "Patients are spared the discomfort of severe skin rashes and may benefit from an enhanced quality of life. Both patients and physicians may also benefit from lack of hypomagnesemia often related to treatment with other anti-EGFR targeted drugs. IGK is pleased to support the NCCS in this investigator-initiated trial of nimotuzumab."

The NCCS is the lead cancer centre coordinating this clinical trial, which will involve approximately 22 institutions from 12 countries worldwide. The trial will treat patients with locally advanced squamous cell cancers of the head and neck immediately following surgery - the "adjuvant setting". Along with standard chemotherapy and radiotherapy, half of the patients will be administered nimotuzumab weekly for an eight week period. The primary endpoint for th
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... , NEW DELHI, India, Dec. 3 /PRNewswire-Asi...Officer at Shenzhen Beike Biotechnology Co. Ltd.,(...ence on High-Risk Diabetic,Foot Care in New Delhi,...g,stem cell research and regenerative medicine com...Indian Podiatry Association (IPA), aimed,to help p...
(Date:12/2/2009)..., NEW YORK, Dec. 2 Reportlinker.... available in its catalogue: ,, Neurostimulati...w.reportlinker.com/p0164232/Neurostimulation---A-G...urostimulation market stands enthused by the growi...e in age-related diseases such as, Parkinson,s, an...
(Date:12/2/2009)...EW YORK, Dec. 2 Nearly ...y makers, and funders today convened to explore no...strategies at the inaugural Partnering for Cures ...ed center of the Milken Institute, convened Partn...orations needed to turn a scientific discovery int...
(Date:12/2/2009)..., CALGARY, Dec. 2 /PRNewswire-FirstCall/ - Onco...) (TSX:ONC; NASDAQ: ONCY ) announced today that in...ering, the underwriters have exercised in full the...al 637,500 units. Each unit is comprised of one co...ant, and was sold at a price of US$3.00 per unit. ...
Breaking Biology Technology:Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4
...een voiced across the state that the recent U.S. ...hree patents held by the patenting and licensing a...astating blow to the state,s acknowledged leadersh... who lodged the thus-far successful challenge agai...em cells held by the Wisconsin Alumni Research Fo...
...n ranks in the lower half of states in federal con... help researchers and companies land more federal ...earch Consortium , funded by a grant from the U.S...otentially lucrative territory - sensitive, classi...Wisconsin through research and development, said J...
...heme-based cities being developed at a phenomenal ...tities of such projects become nightmares. In size... a single large dwelling. , ,Now this requires a n...the customers with other traditional metropolises....City has become great success story, which extend...
Other Biology Technology:Patent ruling doesn't tarnish Wisconsin's stem cell leadership 2Patent ruling doesn't tarnish Wisconsin's stem cell leadership 3Research consortium aims to bring security and defense contracts to Wisconsin 2Branding around the community brand concept 2Branding around the community brand concept 3
(Date:12/3/2009)...nd Rapids, Mich. (Dec. 3, 2009) Van Andel Resea...recisely how the plant hormone abscisic acid (ABA)...nd to environmental stresses such as drought and c...ture , could help engineer crops that thrive in ha...l food shortages. The findings could also have im...
(Date:12/3/2009)... UK leads the world when it comes to investment in...eering and Physical Sciences Research Council (EPS...is needed: "Scientific and engineering research ha...solar power solutions, but more investment is need...ons if we are to meet our carbon emission targets ...
(Date:12/2/2009)...HILADELPHIA New study results strengthen the evid...period of time have an increased risk for developi...er risk factors. , "This provides one more reas...said senior author Michael J. Thun, M.D., M.S., vi...ce research at the American Cancer Society. "Color...
Breaking Biology News(10 mins):VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3Research is vital to a cleaner, greener, low carbon future 2Cigarette smoking increases colorectal cancer risk 2Medela Recognizes National Prematurity Awareness Month With Virtual Human Milk Collection Campaign 5900 1Medela Recognizes National Prematurity Awareness Month With Virtual Human Milk Collection Campaign 5900 2Medela Recognizes National Prematurity Awareness Month With Virtual Human Milk Collection Campaign 5900 3Aflex Unveils Revolutionary New Hose Design for the Chemical and Process Industry 5897 1Aflex Unveils Revolutionary New Hose Design for the Chemical and Process Industry 5897 2InteRNA Technologies and Dana Farber Cancer Institute to Collaborate on the Role of microRNAs in Cancer Pathways 60492 1InteRNA Technologies and Dana Farber Cancer Institute to Collaborate on the Role of microRNAs in Cancer Pathways 60492 2
... that Xanex or Xanax? Or maybe Zantac? If you,re a...fference--mistakes can be fatal. , An estimated 1....jured each year from medication errors, and the U....ing to reduce the possibilities of these errors, s... an injection of Narcan but received Norcuron and ...
...the January 1 issue of Genes & Development, Dr... inhibitor, Mdm2, as a promising target for cancer...tical role in cancer formation, and many anticance...tumor formation. Mdm2 is a key inhibitor of p53 an...ctivity in cells. However, conflicting evidence ex...
... risk of serious suicide attempts or death by suic...s start taking antidepressant medication, accordin...esearchers and published in the January issue of T...found that the risk of suicidal behavior after sta...than the risk posed by older medications. , These...
Other Biology News:Computer scientist sorts out confusable drug names 2Suicide risk does not increase when adults start using antidepressants, study finds 2
MetaMorph from Universal Imaging Corporation (a subsidiary of Molecular Devices)
...olecular Devices is a fully-integrated true point-... and analysis of images for high throughput cell-b...taXpress, a complete software solution for screeni...ress enables users to select a standard image anal...
Varian 2200 Ion Trap GC/MS from Varian, Inc.
... quantification of the green complex formed betwee...te. The rapid color formation from the reaction ca...(600-660 nm) or on a plate reader. The non-radioac...o offer superior sensitivity and prolonged shelf l...
Biology Products: